In contrast, PROVEAN could accurately predict deleterious variants for other tumor suppressors, such as MSH2, (22 of 23 deleterious mutations correctly predicted) as shown in the EP dataset, where PROVEAN displayed a sensitivity of 74.37%. This evidence concerns the gene MSH2 and neoplasm.